Glioblastoma (GBM) is the most common malignant brain tumor, and particularly 30 difficult to treat due to its inherent heterogeneity, which is promoted by a variety of genetic drivers. A lack of models that robustly recapitulate heterogeneity has been a major obstacle for research progress on this disease. Here we show that neural progenitor cells derived from human induced pluripotent stem cells, CRISPR/Cas9 engineered with different combinations of authentic GBM-related genetic drivers give rise to GBM models that recapitulate the 35 pathobiology of this tumor, including inter-and intra-tumor heterogeneity, differential drug sensitivity, extrachromosomal DNA amplifications, and rapid clonal evolution. Different models
established with this approach could serve as a platform for longitudinal assessment of drug treatment sensitivity governed by subtype-specific driver mutations.
One Sentence Summary: hiPSC-derived GBMs recapitulate disease.
Main Text: GBM, the most common primary malignant tumor of the central nervous system (1), has been studied using different varieties of tumor models. Transgenic mouse models (2) and 5 engineered human astrocyte-derived models (3, 4) have been utilized for decades, but application of exogenous viral factors such as SV40 T/t-Ag, HPV E6, and E7, or mutations of genes not commonly affected in GBM such as Src, K-ras, and H-ras have the potential to make these models dissimilar to the actual disease. Patient derived xenograft (PDX) models do overcome such limitations (5), but acquired passenger mutations make it difficult to study the effect of each 10 driver mutation on different characteristics of this disease, and their direct effects on tumor initiation and evolution can only be inferred based on single cell sequencing and phylogenetic relationships.
We reasoned that introducing combinations of mutations identified by The Cancer Genome Atlas (6, 7) as GBM driver mutations into human neural progenitor cells (NPCs), potential cells of 15 origin of GBM (8), could generate a model for studying different types of GBM in the context of an isogenic background. We first introduced two different combinations of driver mutations into human induced pluripotent stem cells (iPSCs) by CRISPR/Cas9 genome editing (9, 10) ( Fig. 1 , A and B). One combination of deletions targeted tumor suppressor genes PTEN and NF1, which are commonly altered together in mesenchymal subtype of GBM (6, 7). A second combination 20 of deletions targeted TP53 and exon 8 and 9 of PDGFRA (PDGFRAΔ8-9). This creates a constitutively active truncating PDGFRA mutation observed in 40% of PDGFRA amplified GBM (11), resulting in a genotype common in the proneural subtype of isocitrate dehydrogenase-wildtype GBM (6, 7). The genetic modifications in single clones were confirmed by genotyping PCR (fig. S1) and RT-PCR (Fig. 1C ). Edited iPSC clones with desired mutations 25 were differentiated into NPCs, using a small molecule protocol (12) and differentiation status was confirmed by downregulation of pluripotency markers, Nanog and Oct4, and corresponding upregulation of NPC markers, Pax6, Nestin, and Sox1 ( fig. S2 ). Confirmation of a neural progenitor state was illustrated by further differentiation into astrocytes, neurons, and oligodendrocytes ( fig. S3 ). 30 We next evaluated if these genetically modified NPCs were capable of forming orthotopic tumors in immunocompromised mice (Fig. 1A) . When edited NPCs were engrafted in the brains of Nod/Scid mice, PTEN -/-;NF1 -/-NPCs and TP53 -/-;PDGFRA wt/Δ8-9 NPCs both formed brain tumors (Fig. 1D ) with a latency of six to nine months. Pathological assessment of these tumors revealed regions of hypercellularity, positivity for GFAP and Olig2, and high expression of Ki- 35 67, features consistent with aggressive tumors with GBM phenotype (Fig. 1D) . In contrast, PTEN -/and TP53 -/singly edited NPCs did not form tumors in the brain over the same time span ( fig. S4, A and B) , while unedited iPSCs formed teratoma-like tumors ( fig. S5 ). Lack of teratomas after NPC injection suggests a high efficiency of differentiation to NPCs with the small molecule protocol. These results illustrate that small numbers of known driver mutations 40 found in GBM are sufficient for phenotypic recapitulation of human tumors in this model system.
One of the benefits of using PDX models in cancer research is that they can be cultured in vitro and be re-engrafted in animals, thus enabling both in vitro and in vivo analyses (13). We evaluated if our induced GBM (iGBM) models could be used in a similar manner. Dissociated tumors obtained from the mouse brains were FACS sorted for human cells using a human MHC antibody, followed by propagation of isolated cells in the same neurosphere conditions used for GBM PDX spheres (14) , which confirmed iGBM sphere formation capability ( Fig. 2A) . These iGBM spheres possessed the same genotypes as the corresponding input NPCs ( fig. S6 ). 5 Extreme limiting dilution assays (15) showed that iGBM spheres had greater self-renewal capacity, a feature of cancer stem cells, when compared to pre-engraftment NPCs (Fig. 2B) , again highlighting gain of cancerous phenotypes of iGBM cells compared to original input cells. The finding that only subpopulations of iGBM sphere cells expressed CD133, (Fig. 2C ) a neural stem cell marker (16), while input NPCs were homogeneously positive for CD133 ( fig. S7 ), 10 further suggests intra-tumor heterogeneity in iGBM subpopulations displaying a cancer stem cell phenotype (17) . We then evaluated if these iGBM-derived sphere cells maintained tumorigenic capacity by secondary orthotopic engraftment ( Fig. 2D ). When injected in the brains of Nod/Scid mice, iGBM-derived sphere cells formed tumors with a shortened latency period of one to two months ( Fig. 2E ). The cells obtained from these secondary iGBM tumors had even 15 greater self-renewal capabilities compared with sphere cells obtained from the primary tumors ( fig. S8 ), suggesting further malignant transformation through in vivo passage. We also tested if these models can be used for in vivo drug treatment experiments comparable to those applied to PDX lines by treating orthotopically engrafted animals with temozolomide (TMZ), a DNAalkylating chemotherapeutic agent used for standard care treatment of GBM patients (18). TP53 -20 /-;PDGFRA wt/Δ8-9 iGBMs proved to be more sensitive to TMZ compared to PTEN -/-;NF1 -/-iGBMs ( Fig. 2F ). PTEN -/-;NF1 -/-iGBMs were found to express higher levels of O 6methylguanine DNA methyl transferase (MGMT) ( Fig. 2G ), which is associated with resistance to TMZ in GBM patients (19), compared to TP53 -/-;PDGFRA wt/Δ8-9 iGBMs, a possible explanation of this differential sensitivity, although MGMT-independent mechanisms in the 25 context of TP53 alteration (20, 21) cannot be eliminated.
We previously reported that extrachromosomal DNA (ecDNA) is prevalent in many cancer types, especially in GBM, and that ecDNA is associated with resistance to drug treatment and rapid evolution of tumor heterogeneity (22, 23). To determine if our iGBM models recapitulated the generation of ecDNA, we first investigated if the original input NPCs possessed karyotype 30 abnormalities or traces of ecDNA. Based on DAPI staining of metaphase spreads and digital karyotyping, edited NPC were karyotypically normal (fig. S9 and S10) as were PTEN -/-;NF1 -/-iGBM cells (Fig. 3A) . In sharp contrast, metaphase spreads of cells obtained from TP53 -/-;PDGFRA wt/Δ8-9 iGBMs showed small DAPI-stained dots adjacent to chromosomes, suggestive of ecDNA ( Fig. 3B ), consistent with our previous findings in GBM tumor samples (23). 35 Furthermore, double minute-like structures became more apparent in the secondary tumors obtained by re-engraftment of the primary spheres ( Fig. 3C ). Those ecDNA incorporated EdU, suggesting replication of those extrachromosomal components (Fig. 3D ). The TP53 -/-;PDGFRA wt/Δ8-9 iGBMs also presented striking numerical and structural chromosome alterations ( Fig. 3E ). This is the first human stem cell-derived cancer model presenting with spontaneous 40 extrachromosomal DNA amplifications, a frequently observed genomic characteristic of cancer (23). The involvement of TP53 in this model might have been crucial for the formation of ecDNA as has been seen in previous mouse model studies (24, 25) .
We further investigated if these iGBMs showed inter-and intra-tumor heterogeneities, which are other notable hallmarks of GBM (26), and have not been recapitulated by previous models. 45 First, the pattern of invasiveness was strikingly different between the two models, with PTEN -/-;NF1 -/-iGBM showing more prominent diffuse invasion compared with TP53 -/-;PDGFRA wt/Δ8-9 iGBM (fig. S11). These tumors were different as well in terms of transcriptomes. Single-cell RNA sequencing (scRNA-seq) was performed using primary iGBM spheres, secondary iGBM tumor cells obtained from orthotopic injection of the primary spheres, and secondary spheres obtained by in vitro culture of the secondary tumor cells ( Fig. 4A ). Transcriptome profiles 5 varied between primary and secondary spheres of the same genotype as well as between spheres and tumors, but the greatest variation occurred between the two iGBM models of different genotypes (Fig. 4 , B and C, fig. S12 ). This is suggestive of inter-tumor heterogeneity between iGBM models which wasnot apparent in pre-engraftment NPCs with different gene edits (fig. S13). These findings suggest that a small number of key driver mutations play an important role 10 in developing such pathognomonic inter-tumor heterogeneity that arises through the process of transformation. When GBM subtype specific genes were analyzed, TP53 -/-;PDGFRA wt/Δ8-9 iGBM showed upregulation of genes characteristic of the proneural subtype, while the PTEN -/-;NF1 -/-iGBM showed a mesenchymal subtype signature ( Fig. 4D, fig. S14 , tables S1 to S4). However, when examined at single cell resolution, each sample shows intra-tumor heterogeneity 15 with different populations of cells presenting signatures of different subtypes ( In summary, we generated a robust system to model human glioblastoma. By introducing 25 different combinations of essential genetic alterations into human iPSCs, resulting tumors faithfully recapitulated hallmarks of GBM pathobiology including histology, gene expression signatures, inter-and intra-tumor heterogeneity, and clonal evolution. Each model presents different characteristics depending on the background genetic alterations, and thus, we expect this to be a useful platform for examining phenotypes resulting from genetic alterations of GBM 30 and other cancer types to derive effective treatments based on specific driver mutations. and serves as a consultant for the company. PSM also did a one-time consultation for Abide Therapeutics, Inc. Data and materials availability: All data are available from the main text and supplementary materials.
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References (28-36) Technologies) . Three million cells were transferred into one well of an uncoated 6-well tissue culture plate and incubated at 37ºC, 5% CO2 on a shaker at 90 rpm. Uniform small EBs formed within 24h and increased in size over the following days. After 48h, a full media change was performed with N2B27 medium supplemented with Dorsomorphin, SB431542, CHIR99021, and 5 Purmorphamine. At this time, about 2/3 of EBs were either discarded or EBs were split across 3 wells of a 6-well plate to reduce the high cell density required initially to ensure uniform formation of embryoid bodies. On days 3-5, half media change was performed with fresh N2B27 media supplemented with Dorsomorphin, SB431542, CHIR99021, and Purmorphamine. On day 6, Dorsomorphin and SB431542 were withdrawn and a full media change with smNPC 10 media (N2B27 media supplemented with 3 µM CHIR99021 and 0.5 µM Purmorphamine) was performed. At this stage, neuroepithelial folds were clearly visible in all EBs. On day 8, EBs were triturated by pipetting 10-15 times with a P1000 pipette and plated onto matrigel-coated 10 cm plates. After 3-4 days, attached EB fragments and outgrown cells were dissociated to single cells with accutase (Innovative Cell Technologies) and split at a 1:6 to 1:8 ratio onto matrigel-15 coated plates. After the first passage, cells were passaged at a 1:10 to 1:15 ratio every 3-6 days.
For the first few passages, large flat non-smNPCs could be observed between smNPC colonies, but progressively disappeared no later than passages 3-6 in almost all cell lines. Total RNA was extracted from the differentiated smNPCs using RNeasy Plus Mini Kit and was reverse transcribed using RNA to cDNA EcoDry Premix according to the manufacturer's instruction. 20 Triplicate qPCR reactions containing cDNA obtained from 10 ng equivalent RNA were run on a CFX96 Real Time System to confirm NPC differentiation with the following reaction conditions: 95ºC for 5 min, 40 cycles of 95ºC for 15 s, 56ºC for 30 s. The data was normalized to GAPDH and the relative transcript levels were determined using 2 -∆ Ct formula. Primers used for the RT-qPCR were listed below. Immunofluorescence microscopy Cells were plated on poly-D-lysine-coated glass coverslips (Thermo Scientific), fixed with 10% 40 formalin (Sigma-Aldrich), blocked with 2% of BSA IgG-free (Jackson ImmunoResearch) and stained with primary antibodies to GFAP (BD Bioscience), Olig2 (Sigma-Aldrich), and Tuj1 (Covance) overnight at 4ºC. Secondary antibody was added for 1 h at room temperature. Coverslips were mounted on microscope glass slides using Fluro-Gel with DAPI (Electron Microscopy Science) followed by visualization using a fluorescent microscope (Keyence).
Intracranial tumor formation
Animal research experiments were conducted under the regulations of the UCSD Animal Care Program, protocol number S00192M. Wildtype and edited smNPCs were dissociated using accutase (Innovative Cell Technologies), washed with PBS, and resuspended at 1x10 6 cells in 2µL PBS supplemented with 0.1% BSA per animal. Resuspended cells were kept on ice and 5 were inoculated into the striatum of 4-6 week-old female Nod/Scid mice (Charles River Laboratory) by stereotactic injections (1.0 mm anterior and 2.0 mm right to the bregma, and 3mm deep from the inner plate of the skull). Wildtype hiPSCs were injected as a control as well. dropped onto humidified glass slides for metaphase cell preparations. DAPI was added to the slides. Images were captured with an Olympus FV1000 confocal microscope. Spectral karyotyping analysis was performed at Applied Spectral Imaging. Genomic DNA extracted from NPCs and iGBM cells using DNeasy blood and tissue kit (Qiagen) was analyzed by digital karyotyping using Illumina HiScan system (Illumina). 25 To detect DNA replication, cells were labeled with EdU and detected using the Click-iT Plus EdU Alexa Fluor 594 imaging kit (Invitrogen). Briefly, cells were pulse labeled with EdU (10 uM) for 1 hour, then allowed to progress to metaphase for 12 hours. KaryoMax (0.1 ug/ml) was added for 3 hours to arrest cells in metaphase. The cells were then collected and metaphase spreads were prepared (23). Cells in metaphase were dropped onto a glass slide, and EdU was 30 detected by applying the Click-iT reaction cocktail directly onto the slides for 20 minutes at room temperature. Slides were then washed with 2X SSC and mounted with anti-fade mounting medium containing DAPI. Cells in metaphase were imaged using an Olympus BX43 fluorescent microscope equipped with a QIClick camera. 35 Single cell RNA sequencing and analysis For the single cell RNA sequencing of secondary tumor cells, the tumors were dissected from mouse brains, cut into small pieces, and then incubated in HBSS (Sigma) containing 1x trypsin (Sigma) at 37° for 20 minutes, followed by mechanical dissociation using glass pipettes to obtain single cells. Cultured sphere cells were dissociated using accutase (Innovative Cell 40 Technologies). Single cells were processed through the Chromium Single Cell Gene Expression Solution using the Chromium Single Cell 3' Gel Bead, Chip and Library Kits v2 (10X Genomics) as per the manufacturer's protocol. In brief, single cells were resuspended in 0.04% BSA in PBS. Ten thousand total cells were added to each channel with an average recovery of 3,040 cells. The cells were then partitioned into Gel Beads in Emulsion in the Chromium 45 instrument, where cell lysis and barcoded reverse transcription of RNA occurred, followed by amplification, shearing and 5′ adaptor and sample index attachment. Agilent High Sensitivity D5000 ScreenTape Assay (Aglient Technologies) was performed for QC of the libraries. Libraries were sequenced on an Illumina NovaSeq. De-multiplexing, alignment to the hg19 transcriptome and unique molecular identifier (UMI)-collapsing were performed using the Cellranger toolkit (version 2.0.1) provided by 10X Genomics. A total of 42,558 cells with 5 approximately 53,000 mapped reads per cell were processed. Analysis of output digital gene expression matrices was performed using the Scanpy v1.3.3 package (30). Matrices for all samples were concatenated and all genes that were not detected in at least 20 single cells were discarded, leaving 20,521 genes for further analyses. Cells with fewer than 600 or more than 8,000 expressed genes as well as cells with more than 80,000 UMIs or 0.1% mitochondrial 10 expressed genes were removed from the analysis. Data were log normalized and scaled to 10,000 transcripts per cell. Top 4,000 variable genes were identified with the filter_genes_dispersion function, flavor='cell_ranger'. PCA was carried out, and the top 25 principal components were retained. With these principal components, UMAP was applied. Single cell and mean expression per sample heatmaps were generated with the pl.heatmap and 15 pl.matrixplot functions, respectively. Mean expression levels for the different gene marker sets were obtained by calculating the fraction of known marker genes found per single cell in each sample and setting the sample mean to 1.
20
RNA sequencing Total RNA was assessed for quality using an Agilent Tapestation, and all samples had RNA Integrity Numbers above 9.0. RNA libraries were generated using llumina's TruSeq Stranded mRNA Sample Prep Kit (Illumina) following manufacturer's instructions. RNA-seq reads were aligned to the human genome (hg19) with STAR 2.4.0h (outFilterMultimapNmax 20, 25 outFilterMismatchNmax 999, outFilterMismatchNoverLmax 0.04, outFilterIntronMotifs RemoveNoncanonicalUnannotated, outSJfilterOverhangMin 6 6 6 6, seedSearchStartLmax 20, alignSJDBoverhangMin 1) using a gene database constructed from Gencode v19 (31, 32). Reads that overlap with exon coordinates were counted using HTSeqcount (-s reverse -a 0 -t exon -i gene_id -m union) (33, 34). Raw read counts were processed with DESeq2 (35) and only genes 30 with mean read count over 20 were considered for the analysis. Raw read counts were transformed using the variance stabilizing transformation function included in DESeq2 (36). Mean and standard deviation of normalized expression were calculated for each gene and Zscores were determined by subtracting the mean from each expression value and dividing by the standard deviation. Table. S3 Fold-change in expression of the signature genes for neural subtype in each sample. Table. S4 Fold-change in expression of the signature genes for classical subtype in each sample. 
